Humulin M3 (30/70) Kwikpen (Insulin Human (Rdna))

Humulin M3 Kwikpen is indicated for use in adults and children with diabetes who require both rapid‑acting and intermediate‑acting insulin to achieve target blood glucose levels.

• Initiation of insulin therapy in newly diagnosed type 1 diabetes mellitus.
• Supplemental basal insulin for patients with type 2 diabetes mellitus inadequately controlled on oral agents.
• Basal‑bolus regimens where a single injection provides both short‑acting and NPH coverage.
• Adjustments during periods of variable carbohydrate intake or physical activity.
• Use in hospital or outpatient settings where a pre‑filled pen simplifies administration.

• Humulin M3 contains recombinant human insulin that binds to insulin receptors on muscle, adipose and hepatic cells. Receptor activation triggers the tyrosine‑kinase signaling cascade, promoting translocation of GLUT‑4 transporters and increasing glucose uptake. The soluble fraction acts rapidly to lower post‑prandial glucose, while the NPH component provides a prolonged effect by delaying absorption, together reducing hepatic glucose production and maintaining basal insulin levels.

Adverse reactions to Humulin M3 Kwikpen are observed in patients and are generally classified by how often they occur.

Common

• Hypoglycemia, presenting as dizziness, sweating, tremor, or confusion due to low blood glucose.
• Local injection‑site reactions such as redness, swelling, itching or mild bruising.
• Lipodystrophy, characterized by localized loss of subcutaneous fat or fatty lump formation.
• Gradual weight gain associated with improved glycemic control and insulin therapy.

Serious

• Severe hypoglycemia that may lead to loss of consciousness, seizures, or the need for emergency assistance.
• Allergic reactions ranging from urticaria and angioedema to rare cases of anaphylaxis.
• Persistent hyperglycemia suggesting insulin resistance or dosing inadequacy.
• Generalized edema or worsening of pre‑existing heart failure, especially in patients with cardiovascular disease.

When prescribing or using Humulin M3 Kwikpen, clinicians should consider several precautionary measures to ensure safe and effective therapy.

• Verify patient’s blood glucose patterns before initiating therapy to avoid overtreatment.
• Adjust dose in renal or hepatic impairment, as insulin clearance may be reduced.
• Monitor for hypoglycemia during periods of fasting, illness, or increased physical activity.
• Use caution in pregnant or breastfeeding women; insulin requirements may change.
• Review concomitant medications that affect glucose metabolism, such as corticosteroids or beta‑blockers.
• Educate patients on proper injection technique and rotation of sites to prevent lipodystrophy.

Humulin M3 Kwikpen may interact with other agents that influence blood glucose or insulin action; awareness of these interactions helps maintain target glycemic control.

Avoid

• Concurrent use of other rapid‑acting insulins or insulin analogues without dose adjustment, which can cause severe hypoglycemia.
• MAO‑B inhibitors combined with certain oral antidiabetics that may potentiate insulin effects.

Use with caution

• Beta‑blockers, which can mask hypoglycemia symptoms.
• Corticosteroids, which raise blood glucose and may require higher insulin doses.
• Thiazide diuretics, which can increase insulin resistance.
• Alcohol, especially in excess, as it may cause unpredictable glucose fluctuations.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) that may affect renal function and insulin clearance.